PharmAbcine

Notifications

Back

Notification settings

Back

Post notifications

Be notified when someone leaves a comment or a reply to your post or comment.

Updates and news

Stay ahead of important updates and news from the site.

Alarm
My account Sign out

Sign-in required.

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Olinvacimab
PMC-309
PMC-402
PMC-403

Recruiting Procedure
Careers Guide
Job Openings

Location
Inquiry
Partnership Request

한국어
English

About Us

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Pipeline

Olinvacimab
PMC-309
PMC-402
PMC-403

For Investors

For Media

Careers

Recruiting Procedure
Careers Guide
Job Openings

Contact

Location
Inquiry
Partnership Request

한국어
English

About Us

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Pipeline

Olinvacimab
PMC-309
PMC-402
PMC-403

For Investors

For Media

Careers

Recruiting Procedure
Careers Guide
Job Openings

Contact

Location
Inquiry
Partnership Request

한국어
English

한국어
English

Core Technology

For Media

Press Release PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

TitlePharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Precl

23 Nov 2023 Views 156

Press Release PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

TitlePharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Tr

9 Nov 2023 Views 523

Press Release PharmAbcine Receives HREC Approval in Australia for the Phase 1a/b Trial of Its Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

TitlePharmAbcine Receives HREC Approval in Australia for the Phase 1a/b Trial of Its Anti-VISTA Anti

18 Sep 2023 Views 899

Press Release PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

TitlePharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel

24 May 2023 Views 1804

Media Center

Subscribe to our website to get latest updates (email@exmaple.com)

Confirm

No
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
Title
Author
Time uploaded
Views
Likes

190
Press Release
Press Release PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
PharmAbcine
23 Nov 2023
Views156
0

189
Press Release
Press Release PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data
PharmAbcine
9 Nov 2023
Views523
0

188
Press Release
Press Release PharmAbcine Receives HREC Approval in Australia for the Phase 1a/b Trial of Its Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
PharmAbcine
18 Sep 2023
Views899
0

187
Press Release
Press Release PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
PharmAbcine
24 May 2023
Views1804
0

186
CEO Story
CEO Story IMAPAC Singapore Biopharma Awards 2023
PharmAbcine
24 Mar 2023
Views1788
0

185
CEO Story
CEO Story Clinical Trials Festival Asia 2023 - IMAPAC
PharmAbcine
20 Jan 2023
Views3140
0

184
CEO Story
CEO Story Dr. Yoo to participate in the 41th Annual J.P. Morgan Healthcare Conference
PharmAbcine
27 Dec 2022
Views2124
0

183
Press Release
Press Release PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
PharmAbcine
13 Dec 2022
Views2367
0

182
CEO Story
CEO Story PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 and JPM@BIO
PharmAbcine
9 Dec 2022
Views1532
0

181
Press Release
Press Release PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week
PharmAbcine
9 Dec 2022
Views1427
0

Previous
1
2
3
4
5
6
7
8
9
Next

About Us
Core Technology
Pipeline
- Olinvacimab
- PMC-309
- PMC-402
- PMC-403
For Investors
For Media
Careers
Contact

LinkedIn I Facebook I YouTube

- 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil,
  Yuseong-gu, Daejeon, 34047, Republic of Korea
- HQ +82-42-863-2017
- R&D Center +82-42-861-2017
- FAX +82-42-863-2080
COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.

2F, Research Building 2, 70,

Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea

HQ +82-42-863-2017

R&D Center +82-42-861-2017

Investor Relations +70-4294-6097

FAX +82-42-863-2080

COPYRIGHT BY PharmAbcine Inc.

ALL RIGHTS RESERVE